Biotech grants in Israel

Between cycles

Supports ARPA inspired high risk demand driven pilots translating new approach methods into practical deep tech practice.

Between cycles

Funds bottom-up research for breakthrough deep-tech, any field of science.

Between cycles

Invests in European deep-tech scale-up ventures with momentum needing capital for commercial expansion.

Between cycles

Runs students and early career scholars with mentoring support for CRF Postdoctoral Research Fellowship in biotechnology, medical technology, and synthetic biology.

Between cycles

Administers research teams and institutions for CRF Research Grant in biotechnology, medical technology, and synthetic biology.

Between cycles

Supports EIC beneficiaries' participation in major trade fairs across the EU, MENA and the US.

Between cycles

Funds early-stage deep tech startups developing solutions at TRL 4-5 in collaboration with industry partners through a 4-month co-creation programme.

Between cycles

Supports international consortia so small companies can turn joint innovation into export-ready products.

Between cycles

Offers market-feasibility support for small companies exploring non-European markets through Europe-wide innovation networks.

Between cycles

Runs themed competitions in which teams compete over several stages to solve one defined technical problem.

Between cycles

Supports early-stage German innovators through a pilot challenge route with mentoring and development funding.

Closed

Pays up to 25 small consortia EUR 200,000 each to test the commercial exploitation potential of results that already came out of earlier Horizon Europe or Horizon 2020 Cluster 4 projects.

Funds clinical trials of prophylactic vaccines against neglected tropical diseases such as schistosomiasis, leishmaniasis and leprosy in sub-Saharan Africa.

Closed

Pays deep-tech start-ups, SMEs and research organisations a €300,000 lump sum in Stage 1, then up to €2.5 million in Stage 2, to push high-risk breakthrough innovations that lack commercial uptake toward real-world, demand-tested deployment.

Closed

Funds early clinical trials of therapies built from the molecules cells secrete rather than the cells themselves, aiming for an off-the-shelf alternative to cell therapy.

Funds research into biomanufactured alternatives to imported natural rubber and fossil-based synthetic rubber for automotive, healthcare and industrial uses.

Funds research into bio-based, biodegradable delivery coatings for fertilisers that replace today's microplastic-shedding polymer coatings.

Funds a full-scale biorefinery that produces bio-based drop-in platform chemicals able to compete directly with their fossil-based equivalents.

Closed

Funds biodiscovery projects that use AI and digital tools to find and sustainably produce new natural compounds from marine and freshwater organisms.

Closed

Funds companies discovering and scaling up bioactive natural compounds from land-based organisms for pharma, cosmetics, food and other markets.

Closed

Funds biotechnology and monitoring tools that remove persistent contaminants from marine, freshwater and groundwater systems.

Closed

Funds early-stage research teams developing climate-resilient crops and plant-based biomanufacturing of high-value nutrients.

Closed

Funds small, SME-majority consortia running an early-phase clinical trial to move a biotech therapy, from antibodies to RNA therapies, from the lab towards the market.

Closed

Pays three European consortia EUR 15 million each to run generative-AI competitions in aerospace, pharma or telecoms, re-granting up to EUR 2 million per finalist SME team that competes.